Avicanna (TSX:AVCN) ROCE % : -35.60% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Avicanna ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Avicanna's annualized ROCE % for the quarter that ended in Mar. 2024 was -35.60%.

Avicanna ROCE % Historical Data

The historical data trend for Avicanna's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna ROCE % Chart

Avicanna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-70.23

-129.38

-116.80

-160.09

-100.29

Avicanna Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-133.75	-87.50	-69.48	-135.11	-35.60

Avicanna ROCE % Calculation

Avicanna's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-8.133	/	( ( (17.619 - 11.405)	+	(21.971 - 11.966) )	/ 2 )
	=	-8.133	/	( (6.214	+	10.005)	/ 2 )
	=	-8.133	/	8.1095
	=	-100.29 %

Avicanna's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-3.52	/	( ( (21.971 - 11.966)	+	(21.536 - 11.768) )	/ 2 )
	=	-3.52	/	( ( 10.005	+	9.768 )	/ 2 )
	=	-3.52	/	9.8865
	=	-35.60 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Avicanna (TSX:AVCN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Avicanna ROCE % Related Terms

Thank you for viewing the detailed overview of Avicanna's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Avicanna (TSX:AVCN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (TSX:AVCN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

AVCNF:USA 0NN:Germany

Address

480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2

Website

https://www.avicanna.com

Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.

Executives

Sheldon Inwentash

10% Security Holder

Avicanna (TSX:AVCN) Headlines

No Headlines